Mannkind CORP 8-K filings

MannKind Corporation announced robust second quarter 2026 financial results, with total revenues surging 43% year-over-year to $109.4 million, bolstered by key product approvals and business updates.

MannKind Corporation announced a $50 million private placement financing, primarily to fund a $45 million CVR payment following FDA approval of Furoscix ReadyFlow.

MannKind Corporation announced FDA approval for Afrezza inhalation powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.

The FDA has released MannKind from a long-standing postmarketing requirement regarding pulmonary malignancy risks for Afrezza.

MannKind Corporation stockholders re-elected nine directors, approved executive compensation, and ratified its auditor.

MannKind Corporation announced first quarter 2026 financial results, with total revenues up 15% year-over-year, driven by commercial product sales and royalties, while advancing key pipeline programs.

MannKind Corporation announced robust fourth quarter and full year 2025 financial results, driven by strong commercial portfolio performance and strategic acquisition of scPharmaceuticals.

MannKind Corporation filed an amended 8-K to include comprehensive financial statements for its scPharma acquisition, detailing pro forma results and financing.

MannKind Corporation announced the discontinuation of its Phase 3 clinical trial for nebulized clofazimine (MNKD-101) due to futility after an analysis of sputum culture conversion data.

MannKind Corporation announced robust third-quarter 2025 financial results, including a 17% revenue increase, alongside significant progress in its product pipeline and the completion of the scPharmaceuticals acquisition.

MannKind Corporation has finalized its acquisition of scPharmaceuticals Inc. for approximately $296.5 million in cash and contingent value rights, funded by existing cash and a new $250 million delayed draw term loan.

MannKind Corporation announced an expanded collaboration with United Therapeutics, adding a new development product to their existing license agreement, including an upfront payment and potential milestones.

MannKind Corporation will acquire scPharmaceuticals Inc. for up to $6.35 per share, diversifying its revenue and expanding into the cardiometabolic market with FUROSCIX.

MannKind Corporation announced second quarter 2025 financial results, reporting a 6% increase in total revenues and significant progress across its pipeline, including a pediatric sBLA submission for Afrezza.

MannKind Corporation held its 2025 Annual Meeting of Stockholders on May 14, 2025, and announced the results of the votes on director elections, executive compensation, and auditor ratification.

Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development at MannKind Corporation, will step down from his executive role and transition to a non-executive employee before his final separation on August 1, 2025.

MannKind Corporation announces positive Q1 2025 financial results with revenue and income growth, alongside progress in its clinical pipeline programs.

MannKind Corporation announces a 43% increase in 2024 revenues to $286 million and advancements in its clinical pipeline.

MannKind Corporation's Executive Vice President, Lauren Sabella, will retire on July 18, 2025, after transitioning to a new role overseeing operations, excluding the Endocrine Business Unit, effective January 6, 2025.

MannKind Corporation has agreed to exchange $193.7 million of its convertible senior notes for 26,749,559 shares of common stock and $89.2 million in cash.

MannKind Corporation announced a 37% increase in total revenue for the third quarter of 2024, driven by strong performance of Tyvaso DPI and advancements in clinical programs.

MannKind Corporation has announced the retirement of director Kent Kresa and the appointment of Steven B. Binder to the Board, effective September 30, 2024.

MannKind Corporation announced a 49% increase in total revenue for the second quarter of 2024, alongside advancements in their orphan lung disease clinical programs.

MannKind Corporation held its 2024 Annual Meeting of Stockholders on May 15, 2024, where all director nominees were elected, executive compensation was approved on an advisory basis, and Deloitte & Touche LLP was ratified as the independent auditor.

MannKind Corporation announced a 63% year-over-year increase in total revenue for the first quarter of 2024, reaching $66 million, and a net income of $11 million.

MannKind Corporation has fully repaid its outstanding debt of approximately $31.6 million and terminated its loan agreement, along with discharging a convertible promissory note for $8.9 million by issuing 1.5 million shares and paying $8.9 million.

MannKind Corporation has appointed Christopher Prentiss as its new Chief Financial Officer, effective April 22, 2024, succeeding Steven B. Binder, who will transition to Executive Vice President, Special Projects.

MannKind Corporation announced a 99% increase in total revenue for 2023, reaching $199 million, and a strong cash position of $302 million.